Test intended for patients 40 years of age or older. Stratifies risk of aggressive prostate cancer in patients with elevated PSA for whom biopsy is being considered. Test should not be ordered if (1) prostate cancer was previously diagnosed; (2) digital rectal exam was performed within the last 4 days; (3) any procedure or therapy was used to treat symptomatic benign prostatic hyperplasia (BPH) within the past 6 months; (4) any invasive, urologic procedure that may be associated with a secondary PSA evaluation was done within the past 6 months; (5) 5-alpha reductase inhibitor (5-ARI) therapy, such as Avodart (dutasteride) or Proscar (finasteride), was administered within the past 6 months.
New York DOH Approval Status
Serum Separator Tube (SST).
Transfer 4 mL serum to an ARUP Standard Transport Tube. (Min: 3 mL)
Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Frozen Serum Separator Tubes (SST).
Biopsy history must be provided at time of order.
Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: 1 month
Performed by non-ARUP Laboratory
4 Kallikrein Biomarkers: Total PSA, Free PSA, percent free PSA, Intact PSA and hK2. Test should not be ordered if Digital Rectal Exam (DRE) has been performed within the last 4 days or if biopsy history is positive.
|Component Test Code*||Component Chart Name||LOINC|
|2014060||4K - Biopsy History||66117-3|
|2014061||4K - Digital Rectal Exam (DRE)||10205-3|
|2014063||4K - Score||19146-0|
|2014309||4K - PSA, Total||83112-3|
|2014310||4K - PSA, Free||83113-1|
|2014311||4K - PSA, Percent Free||12841-3|
- 4K Prostate Screen; Prostate test
- Kallikrein score